Sarepta Therapeutics is a biotechnology company focused on pioneering innovative gene therapies for the treatment of rare genetic diseases, particularly those affecting muscle disorders
The company is dedicated to developing therapies that can enable patients with conditions like Duchenne Muscular Dystrophy to achieve improved outcomes and quality of life. With a strong emphasis on research and development, Sarepta utilizes advanced techniques such as RNA-targeted therapies and gene editing to combat genetic disorders at their source. Through its work, the company aims to transform the landscape of genetic medicine and provide hope for individuals and families affected by these challenging diseases.
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.
Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.
Arrowhead Pharmaceuticals Inc. (NASDAQARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. NASDAQ: SRPTNASDAQSRPT)
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments, and gene therapy.
